Ligand Additional Paid In Capital from 2010 to 2025
| LGND Stock | USD 109.70 1.61 1.49% |
Additional Paid In Capital | First Reported 2011-06-30 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 202.2 M |
Check Ligand Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 M, Interest Expense of 2.9 M or Total Revenue of 104.5 M, as well as many indicators such as Price To Sales Ratio of 9.21, Dividend Yield of 0.42 or PTB Ratio of 4.46. Ligand financial statements analysis is a perfect complement when working with Ligand Pharmaceuticals Valuation or Volatility modules.
Ligand | Additional Paid In Capital |
Latest Ligand Pharmaceuticals' Additional Paid In Capital Growth Pattern
Below is the plot of the Additional Paid In Capital of Ligand Pharmaceuticals Incorporated over the last few years. Additional Paid In Capital (or APIC) is an accounting term found on Ligand Pharmaceuticals Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x Ligand Pharmaceuticals Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of Ligand Pharmaceuticals Incorporated shares and does not have any impact on the value of APIC. It is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. Ligand Pharmaceuticals' Additional Paid In Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ligand Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Additional Paid In Capital | 10 Years Trend |
|
Additional Paid In Capital |
| Timeline |
Ligand Additional Paid In Capital Regression Statistics
| Arithmetic Mean | 514,928,518 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 80.56 | |
| Mean Deviation | 386,196,388 | |
| Median | 798,205,000 | |
| Standard Deviation | 414,844,665 | |
| Sample Variance | 172096.1T | |
| Range | 963.8M | |
| R-Value | 0.88 | |
| Mean Square Error | 42268.8T | |
| R-Squared | 0.77 | |
| Slope | 76,498,336 | |
| Total Sum of Squares | 2581441.4T |
Ligand Additional Paid In Capital History
About Ligand Pharmaceuticals Financial Statements
Ligand Pharmaceuticals stakeholders use historical fundamental indicators, such as Ligand Pharmaceuticals' Additional Paid In Capital, to determine how well the company is positioned to perform in the future. Although Ligand Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ligand Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ligand Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ligand Pharmaceuticals Incorporated. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Additional Paid In Capital | 917.9 M | 963.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Ligand Pharmaceuticals Correlation against competitors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth 0.524 | Return On Assets |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.